Thus, managing post-transcriptional NLRP3 priming at various levels, such as blocking NF-κB activation to downregulate the NLRP3 gene expression, might offer avenues to treat or prevent inflammatory outbreaks in CAPS patients40. Here, NFKB1 is linked to cryopyrin-associated periodic syndrome.